Commentary Open Access
Volume 2 | Issue 4 | DOI: https://doi.org/10.33696/diabetes.1.028
Can Monoclonal Antibodies against CGRP Offer New Treatment Options for Type 2 Diabetes?
Celine E Riera1,2,*
- 1Center for Neural Science and Medicine, Department of Biomedical Sciences, Board of Governors Regenerative Medicine Institute, Department of Neurology, Cedars-Sinai Medical Center, 127 South San Vicente Boulevard, Los Angeles CA 90048, USA
- 2David Geffen School of Medicine, University of California, Los Angeles, USA
Corresponding Author
Celine E Riera, Celine.riera@cshs.org
Received Date: November 20, 2020
Accepted Date: December 29, 2020
Riera CE. Can Monoclonal Antibodies against CGRP Offer New Treatment Options for Type 2 Diabetes?. J Diabetes Clin Res. 2020; 2(4):114-118.
Copyright: © 2020 Riera CE. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
Chimeric Antigen Receptor CAR NK Cells Emerging Immunotherapy for the Treatment of Cancer
Although NK cells are recognized as effector lymphocytes of the innate immune system, they also regulate the adaptive immune response by releasing inflammatory cytokines and developing immunological memory. Unlike other lymphocytes such as T or B cells, NK cells do not express rearrangeable, antigen-specific receptors.
Gender Disparities in Outcomes Following Pulmonary Embolism Treatment in the Intensive Care Unit; A Multi-center Retrospective Cohort Study
Pulmonary embolism (PE) is a blockage of blood flow in the pulmonary artery bed that can result in a life-threatening and potentially reversible right ventricular failure [1]. PE remains one of the leading causes of poor prognosis and death, particularly when a shock or right ventricular failure occurs [2]. According to studies, PE is generally manifested in a nonspecific manner
Hepatitis Treatment in the Last 20 Years: A Short Review
The hepatitis C virus (HCV) genome was isolated during the late 1980s using molecular cloning techniques. It is recognized as the cause of most cases of percutaneously transmitted non-A, non-B hepatitis. It is estimated, that up to 200 million people worldwide are infected with the hepatitis C virus (HCV), more than 3% of the world population. The predominant risk factors for HCV are intravenous drug use, tattoos, exposure to blood products, occupational risk and ethnicity.
Mega-Dose Dietary Riboflavin in Treatment in Keratoconus, Post-Refractive Cornea Ectasia and Migraine. Has Its Time Arrived?
Recently, several studies and investigators have shown the beneficial effects of high dose dietary riboflavin (vitamin B2) in the treatment of keratoconus, post-refractive (LASIK, PRK & Radial Keratotomy) ectasia (with sunlight exposure) and patients treated with our own protocol (NIH Clinical Study – www.clinicaltrials.gov - # NCT 03095235) discovered significant relief for intractable migraine headaches and/or ophthalmic migraine (classic migraine visual symptoms without headache).
Lipoprotein Apheresis: First FDA Indicated Treatment for Elevated Lipoprotein(a)
Lipoprotein(a) [Lp(a)] is a genetically determined lowdensity lipoprotein (LDL) particle that is comprised of apolipoprotein(a) [apo(a)] and apolipoprotein B-100 (apoB) moieties. It is well-established that elevated Lp(a) is an independent risk factor for cardiovascular disease (CVD).